Ocular Therapeutix Inc
OCUL
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.06B
Close$
$-1.81
117.9% downside
Current Fair Value
117.9% downsideOvervalued by 117.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.06 Billion |
|---|---|
| Enterprise Value | $1.48 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.42 |
| Beta | 0.9 |
| Outstanding Shares | 224,099,410 |
Return
| Return on Equity | -49.95% |
|---|---|
| Return on Assets | -39.66% |
| Return on Invested Capital | -43.16% |
Valuation & Multiples
| P/E Ratio | -7.27 |
|---|---|
| PEG | -18.97 |
| Price to Sales | - |
| Price to Book Ratio | 5.06 |
| Enterprise Value to Revenue | 28.39 |
| Enterprise Value to EBIT | -5 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.14 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 11, 2026
EPS Estimate
$-0.32
Average shareholder expectationRevenue Estimate
$12.56 M
Average shareholder expectationNext Earnings Call
Expected Date
August 4, 2026
EPS Estimate
$-0.40
Average shareholder expectationRevenue Estimate
$13.20 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.0398▲ 58.68% |
|---|---|
| Total Calls | 2,172,800▼ 33.04% |
| Total Puts | 2,259,300▲ 53.68% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 110.41%▲ 8.11% |
|---|---|
| Total Invested | $1.77B▼ 24.08% |
| Investors Holding | 284▲ 19.00% |
ESG Score
No data
About Ocular Therapeutix Inc
CEO: Antony Mattessich